Meet Prostate Cancer Surgeon James Eastham
James A. Eastham, MD, FACS
Chief, Urology Service; Peter T. Scardino Chair in Oncology
Prostate Cancer; Nerve-Sparing Techniques; Salvage Radical Prostatectomy; Robotic Prostatectomy
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Eastham accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, University of Southern California, Los Angeles
Urology - Los Angeles County - University of Southern California Medical Center
Urologic Oncology - Baylor College of Medicine
I am a surgeon who specializes in nerve-sparing radical prostatectomy for the treatment of prostate cancer and salvage radical prostatectomy in patients with prostate cancer in whom radiation therapy has failed. I completed my fellowship in urologic oncology in 1995 and have been in practice since then, devoting the past 15 years exclusively to the care of men with prostate cancer.
I see about 300 men with prostate cancer each year. Many of them have low-risk disease and are candidates for active surveillance, meaning that no immediate treatment is necessary. In this approach, we monitor the tumor closely for signs that it might be growing or becoming more aggressive and hold off on treatment. For those men with more high-risk cancer that requires treatment, I primarily perform robotic-assisted radical prostatectomy.
At MSK, our treatment recommendations are based on personal risk. Not all men have the same risk — one size does not fit all. Many prostate cancers are of such low risk that treatment would only result in possible side effects, without improving patients’ life expectancy. Such cancers are best managed with active surveillance. Other men will benefit from either surgery or radiation therapy.
While most men are candidates for robotic surgery, some may still do better with traditional open surgery, a procedure I also perform. An area of special interest to me is men with high-risk prostate cancer who might not have been considered candidates for traditional open surgery. This includes men who have previously been treated with radiation therapy but whose cancer has returned.
My clinical research focuses on improving outcomes following surgery for prostate cancer. This includes controlling the cancer and restoring normal urinary and sexual function. Together with my colleagues in medical oncology and radiation oncology, we tailor therapy as accurately as possible to each individual’s cancer to control or cure it while minimizing treatment-related side effects.
We’re also starting to investigate the role of local treatment — surgery or radiation — in selected men with low-volume metastatic prostate cancer, meaning that their cancer has spread to a limited number of other sites in the body. Such men have traditionally been treated only with hormonal therapy. We are now investigating using a therapy in which men receive systemic treatment, such as chemotherapy, plus local treatment. The goal is to prolong survival and, ultimately, cure the cancer.
In addition, certain carefully selected men may be candidates for focal therapy, in which just the area of the prostate with the cancer is treated rather than the entire gland. This approach reduces the risk of treatment side effects while still eradicating the cancer.
During the course of my career I’ve given more than 180 invited presentations at meetings and symposia in the United States and around the world. I have also published 300 peer-reviewed studies in prestigious national and international journals.
As a doctor, my focus is on the whole person, not just his disease. I want my patients to be alive, but also to be able to live full and enjoyable lives.
As a doctor, my focus is on the whole person, not just his disease.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2010-2020)
- Phi Beta Kappa
- Alpha Omega Alpha
- National Kidney Foundation Research Fellowship Award
- American Cancer Society Clinical Fellowship Award
- Lamar Fleming Award-Gene Therapy in Prostate Cancer
- Patients’ Choice: Rated & Awarded by Patients
- Best Clinical Paper Published in European Urology in 2011: “Salvage Radical Prostatectomy for Radiation-Recurrent Prostate Cancer: A Multi-institutional Collaboration”
- Clinical Trials Investigated by Dr. Eastham
- A Phase I Study of Photodynamic Therapy in People with Recurrent Prostate Cancer
- Clinical Trials Co-Investigated by Dr. Eastham
- A Study of Multi-Modality Therapy for Very High-Risk Localized and Low-Volume Prostate Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Books and Book Chapters
“Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy.” Eastham JA, Scardino PT. In: Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Vogelzang NJ, Scardino PT, Shipley WU, DF Coffey, eds. Baltimore: Lippincott Williams and Wilkins; 2006: 306-314.
“Nerve-sparing radical retropubic prostatectomy.” Eastham JA, Jarrard DF. In: Atlas of the Prostate. 3rd ed. Scardino PT, Slawin KM, eds. Philadelphia: Current Medicine; 2006: 145-161.
“Preservation of sexual function after treatment for prostate cancer.” Eastham JA. In: Prostate Cancer: Principles and Practice. Kirby RS, Partin AW, Feneley M, Parsons JK, eds. Abington, UK: Taylor & Francis; 2006: 675-682.
“Expectant management of prostate cancer.” Eastham JA, Scardino PT. In: Campbell’s Urology. 9th ed. Kavoussi LR, Novick AC, Partin AW, Wein AJ, eds. Philadelphia: WB Saunders; 2007.
“Cancer of the prostate.” Zelefsky MJ, Eastham JA, Sartor AO. In: DeVita, Hellman, and Rosenberg’s: Cancer Principles & Practice of Oncology. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: 1220-1279.
Visit PubMed for a full listing of Dr. Eastham’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James A. Eastham discloses the following relationships and financial interests:
Simulated Inanimate Models, LLC
Ownership / Equity Interests
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.